NDA 204370 · Abbvie
Vraylar
Cariprazine Hydrochloride · Oral · Atypical Antipsychotic
NovelLast checked: Nov 20, 2026Latest source record: Dec 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Sep 17, 2015
Approved uses
9
Original approval plus efficacy supplements
Registered trials
53
23 Phase 3, 6 recruiting
FAERS reports
9,636
3,459 serious, 258 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. VRAYLAR is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions ( 5.1 )]. Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for the emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.2 )] . The safety and effectiveness of VRAYLAR have not been established in pediatric patients [see Use in Specific Populations ( 8.4 )]....
What it is approved for
From the label in effect Nov 11, 2026.
VRAYLAR ® is indicated for: Treatment of schizophrenia in adults [see Clinical Studies ( 14.1 )] Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies ( 14.2 )] Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults [see Clinical Studies ( 14.3 )] Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14.4 )] VRAYLAR is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults ( 1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults ( 1 ) Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults ( 1 ) Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults ( 1 )
Mechanism: The mechanism of action of cariprazine is unknown. However, the efficacy of cariprazine could be mediated through a combination of partial agonist activity at central dopamine D 2 and serotonin 5-HT 1A receptors and antagonist activity at serotonin 5-HT 2A receptors. Cariprazine forms two major metabolites, desmethylcariprazine (DCAR) and didesmethylcariprazine (DDCAR), that have in vitro receptor binding profiles similar to the parent drug.
Therapeutic areas: Psychiatry
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 18, 2025 Supplement 17 · Efficacy · priority review LetterLabel
- Dec 18, 2025 Supplement 15 · Efficacy · priority review LetterLabel
- Dec 18, 2025 Supplement 16 · Efficacy · priority review LetterLabel
- Dec 18, 2025 Supplement 14 · Efficacy LetterLabel
- Dec 16, 2022 Supplement 9 · Efficacy LabelLetterReview
- May 24, 2019 Supplement 6 · Efficacy LabelLetterReview
- Nov 9, 2017 Supplement 2 · Efficacy LabelLetter
- Sep 17, 2015 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
- Sep 17, 2015 Original approval · Efficacy Novel
6 products under this application
- VRAYLAR · CARIPRAZINE HYDROCHLORIDE EQ 0.75MG BASE · CAPSULE, ORAL · Prescription
- VRAYLAR · CARIPRAZINE HYDROCHLORIDE EQ 6MG BASE · CAPSULE, ORAL · Prescription · TE AB
- VRAYLAR · CARIPRAZINE HYDROCHLORIDE EQ 3MG BASE · CAPSULE, ORAL · Prescription · TE AB
- VRAYLAR · CARIPRAZINE HYDROCHLORIDE EQ 0.5MG BASE · CAPSULE, ORAL · Prescription
- VRAYLAR · CARIPRAZINE HYDROCHLORIDE EQ 4.5MG BASE · CAPSULE, ORAL · Prescription · TE AB
- VRAYLAR · CARIPRAZINE HYDROCHLORIDE EQ 1.5MG BASE · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Cariprazine" as an intervention, any sponsor and status, largest first.
- Sequential Multiple Assignment Randomized Trial for Bipolar DepressionPivotal-lookingActive, not recruiting
Massachusetts General HospitalAcademic, hospital or other
NCT06433635 · 2,726 participants (planned) · Start Oct 1, 2024 · Primary completion Feb 28, 2030
Drug: Cariprazine; Aripiprazole/Escitalopram combination and 2 more · For: Bipolar I Disorder; Depression
Sites: Birmingham, Alabama; Bloomington, Indiana; Baltimore, Maryland · 18 sites in all
- Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)Pivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01715805 · 1,022 participants · Start Nov 15, 2012 · Primary completion Jun 24, 2016
Drug: Cariprazine; Placebo and 1 more · For: Major Depressive Disorder
Sites: Tucson, Arizona; Little Rock, Arkansas; Cerritos, California · 85 sites in all
- A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed FeaturesPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT03573297 · 901 participants · Start Jun 15, 2018 · Primary completion Sep 5, 2022
Drug: Cariprazine; Placebo · For: Bipolar I Disorder; Mania; Depression
Sites: Little Rock, Arkansas; Rogers, Arkansas; Anaheim, California · 108 sites in all
- Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive DisorderPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01469377 · 819 participants · Start Dec 15, 2011 · Primary completion Dec 12, 2013
Drug: Placebo; Cariprazine · For: Major Depressive Disorder
Sites: Garden Grove, California; National City, California; Oceanside, California · 72 sites in all
- A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With SchizophreniaPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01412060 · 765 participants · Start Sep 27, 2011 · Primary completion Sep 3, 2014
Drug: Placebo; Cariprazine · For: Schizophrenia
Sites: Little Rock, Arkansas; Cerritos, California; Costa Mesa, California · 73 sites in all
AbbVieAbbVie (ABBV)
NCT03738215 · 759 participants · Start Nov 9, 2018 · Primary completion Sep 30, 2021
Drug: Cariprazine; Placebo · For: Major Depressive Disorder
Sites: Phoenix, Arizona; Little Rock, Arkansas; Rogers, Arkansas · 125 sites in all
AbbVieAbbVie (ABBV)
NCT03739203 · 752 participants · Start Nov 10, 2018 · Primary completion Sep 6, 2021
Drug: Cariprazine; Placebo and 1 more · For: Major Depressive Disorder
Sites: Dothan, Alabama; Little Rock, Arkansas; Anaheim, California · 112 sites in all
- Long-term Study of Cariprazine in Patients With SchizophreniaPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01104792 · 752 participants · Start May 31, 2010 · Primary completion Jan 31, 2013
Drug: Cariprazine · For: Schizophrenia
Sites: Little Rock, Arkansas; Springdale, Arkansas; Carson, California · 86 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use1,083
- drug ineffective566
- weight increased501
- akathisia434
- anxiety392
- tardive dyskinesia392
- tremor378
- nausea373
- fatigue368
- insomnia354
- suicidal ideation337
- depression296
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 2 |
| 2015 | 1 |
| 2016 | 156 |
| 2017 | 337 |
| 2018 | 415 |
| 2019 | 890 |
| 2020 | 1,030 |
| 2021 | 853 |
| 2022 | 850 |
| 2023 | 1,259 |
| 2024 | 1,294 |
| 2025 | 1,516 |
| 2026 | 1,033 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vraylar (Cariprazine HCl)
2024 spending
$1.14B
Beneficiaries
117,573
766,962 claims
Per beneficiary
$9,662
$48.73 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $487,495,093 |
| 2021 | $583,108,993 |
| 2022 | $708,765,555 |
| 2023 | $935,653,082 |
| 2024 | $1,135,973,310 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis.
Nuñez NA, Joseph B, Pahwa M, et al. · J Affect Disord 2022 · Network Meta-Analysis, Research Support, N.I.H., Extramural
- Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis.
Schneider-Thoma J, Chalkou K, Dörries C, et al. · Lancet 2022 · Systematic Review, Network Meta-Analysis
- Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.
Pillinger T, McCutcheon RA, Vano L, et al. · Lancet Psychiatry 2020 · Comparative Study, Network Meta-Analysis
- Adjunctive Antipsychotics in Major Depressive Disorder: A Systematic Review and Network Meta-Analysis.
McIntyre RS, Stahl SM, Shim SR, et al. · JAMA Psychiatry 2026 · Systematic Review, Network Meta-Analysis
- Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis.
Yildiz A, Siafis S, Mavridis D, et al. · Lancet Psychiatry 2023 · Systematic Review, Network Meta-Analysis
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.